TY  - JOUR
AU  - Ziegler, Nicole
AU  - Cortés-López, Mariela
AU  - Alt, Francesca
AU  - Sprang, Maximilian
AU  - Ustjanzew, Arsenij
AU  - Lehmann, Nadine
AU  - El Malki, Khalifa
AU  - Wingerter, Arthur
AU  - Russo, Alexandra
AU  - Beck, Olaf
AU  - Attig, Sebastian
AU  - Roth, Lea
AU  - König, Julian
AU  - Paret, Claudia
AU  - Faber, Jörg
TI  - Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL.
JO  - OncoImmunology
VL  - 12
IS  - 1
SN  - 2162-4011
CY  - Abingdon
PB  - Taylor & Franics
M1  - DKFZ-2023-00451
SP  - 2184143
PY  - 2023
AB  - Despite massive improvements in the treatment of B-ALL through CART-19 immunotherapy, a large number of patients suffer a relapse due to loss of the targeted epitope. Mutations in the CD19 locus and aberrant splicing events are known to account for the absence of surface antigen. However, early molecular determinants suggesting therapy resistance as well as the time point when first signs of epitope loss appear to be detectable are not enlightened so far. By deep sequencing of the CD19 locus, we identified a blast-specific 2-nucleotide deletion in intron 2 that exists in 35
KW  - B-ALL (Other)
KW  - CART19 therapy (Other)
KW  - CD19 (Other)
KW  - CD20 (Other)
KW  - NONO (Other)
KW  - PTBP1 (Other)
KW  - RBP (Other)
KW  - isoforms (Other)
KW  - splicing (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36875548
C2  - pmc:PMC9980455
DO  - DOI:10.1080/2162402X.2023.2184143
UR  - https://inrepo02.dkfz.de/record/274141
ER  -